ZEVRA THERAPEUTICS

September 13, 2023

NasdaqGS: ZVRA

Cautionary Note Regarding Forward-Looking Statements

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue,” “could,” “intend,” “target,” “predict,” or the negative versions of those words or other comparable words or expressions, although not all forward-looking statements contain these identifying words or expressions. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements include statements regarding the promise and potential impact of our preclinical or clinical trial data or Acer Therapeutics Inc.’s (“Acer’s”) clinical trial data, including without limitation the timing and results of any clinical trials or readouts, the consummation and timing of the transaction, our anticipated financial performance, including anticipated closing of and synergies related to the transaction, our industry, business strategy, plans, goals and expectations concerning our market position, future operations, the timing or results of any Investigational New Drug applications and NDA submissions, including the resubmission of the NDA for arimoclomol, communications with the FDA, the potential uses or benefits of arimoclomol, KP1077, SDX or any other product candidates for any specific disease indication or at any dosage, the potential benefits of any of’ Zevra’s product candidates, the success or timing of the launch or commercialization of AZSTARYS® or any other products or related sales milestones, the sufficiency of cash to fund operations, our plans or ability to seek funding, our plans with respect to our share repurchase program, and our strategic and product development objectives. These forward-looking statements are based on information currently available to Zevra and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: uncertainties as to the timing of the consummation of the proposed transactions and the ability of the parties to consummate the proposed transactions; the satisfaction of the conditions precedent to consummation of the proposed transactions, including the approval of Acer's stockholders; the ability to obtain required regulatory approvals at all or in a timely manner; any litigation related to the proposed transaction; disruption of Acer's or Zevra's current plans and operations as a result of the proposed transaction; the ability of Acer or Zevra to retain and hire key personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the proposed transaction; the ability of Zevra to successfully integrate Acer's operations, products, product candidates and technology ; the ability of Zevra to implement its plans, forecasts and other expectations with respect to Acer's business after the completion of the transaction and realize additional opportunities for growth and innovation; the ability of Zevra to realize the anticipated synergies and related benefits from the proposed transaction in the anticipated amounts or within the anticipated timeframes or at all; and the ability to maintain relationships with Zevra's and Acer's respective employees, customers, other business partners and governmental authorities. These and other important factors are discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 7, 2023, as updated by our Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023, and in our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made herein.

While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to this presentation.

This presentation also may contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Important Additional Information Regarding Transactions to be Filed with the SEC

In connection with the proposed transaction(s), Zevra Therapeutics, Inc. (Zevra) and Acer Therapeutics, Inc. (Acer) will file relevant materials with the SEC, including a Zevra registration statement on Form S-4 that will include a proxy statement of Acer and will also constitute a prospectus of Zevra, and a definitive proxy statement will be mailed to stockholders of Acer. INVESTORS AND SECURITY HOLDERS OF ZEVRA AND ACER ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS THAT WILL BE INCLUDED IN THE REGISTRATION STATEMENT ON FORM S-4, AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTIONS OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT/PROSPECTUS (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS, THE PARTIES TO THE PROPOSED TRANSACTIONS AND THE RISKS ASSOCIATED WITH THE PROPOSED TRANSACTIONS. Investors and security holders will be able to obtain, without charge, a copy of the registration statement, the proxy statement/prospectus and other relevant documents filed with the SEC (when available) from the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by Zevra will be available free of charge on Zevra's investor relations website at investors.zevra.com under the tab "SEC Filings." Copies of the documents filed with the SEC by Acer will be available free of charge on Acer's investor relations website at www.acertx.com/investor-relations under the tab "SEC Filings."

Participants in the Solicitation

Zevra, Acer and certain of their directors, executive officers and other members of management may be deemed to be participants in the solicitation of proxies with respect to the proposed transactions. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders of Acer in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information regarding Zevra's directors and executive officers is contained in Zevra's definitive proxy statement, which was filed with the SEC on March 15, 2023, the definitive proxy statement filed by Daniel J. Mangless, together with the other participants named therein, which was filed with the SEC on March 17, 2023, and Zevra's Current Reports on Form 8-K, filed with the SEC on March 30, 2023, May 8, 2023, May 15, 2023, and August 7, 2023. Information regarding Acer's directors and executive officers is contained in Acer's definitive proxy statement, which was filed with the SEC on April 14, 2023. Security holders and investors may obtain additional information regarding the interests of such persons, which may be different than those of Zevra's security holders generally, by reading the proxy statement/prospectus and other relevant documents regarding the transactions, which will be filed with the SEC. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at www.sec.gov and Zevra's or Acer's investor relations websites as described above.

No Offer or Solicitation

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. In connection with the proposed transactions, Zevra will file a registration statement on Form S-4 that will include a proxy statement of Acer and will also constitute a prospectus of Zevra. INVESTORS AND SECURITY HOLDERS OF ZEVRA AND ACER ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

OLPRUVA™ Important Safety Information

OLPRUVA [ol proo vah] (sodium phenylbutyrate) for oral suspension

This summary does not include all information about OLPRUVA and is not meant to take the place of discussions with your healthcare provider about your or your child's treatment. Please read this important information carefully and discuss any questions about OLPRUVA with your healthcare provider.

What is OLPRUVA?

- OLPRUVA is a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children weighing 44 pounds (20 kg) or greater and with a body surface area (BSA) of 1.2 m^2 or greater, with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).
- Episodes of rapid increase of ammonia in the blood (acute hyperammonemia) may happen in people during treatment with OLPRUVA. OLPRUVA is not for the treatment of acute hyperammonemia, which can be life-threatening and requires emergency medical treatment.
- OLPRUVA is not approved in children weighing less than 44 pounds (20 kg) or in children weighing 44 pounds (20 kg) or greater with a BSA of less than 1.2 m^2.

Before taking OLPRUVA, tell your or your child's healthcare provider about all your medical conditions, including if you:

- have heart problems
- have kidney or liver problems
- are pregnant or plan to become pregnant. It is not known if OLPRUVA will harm your unborn baby. If you become pregnant during treatment with OLPRUVA, call Acer Therapeutics Inc. at 1-833-657-7882 to report the pregnancy.
- are breastfeeding or plan to breastfeed. It is not known if OLPRUVA passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take OLPRUVA.

Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with OLPRUVA. Especially tell your healthcare provider if you or your child take:

- corticosteroids
- valproic acid
- haloperidol
- probenecid

Know the medicines you take. Keep a list of them to show your or your child's healthcare provider and pharmacist when you get a new medicine.

Keep OLPRUVA and all medicines out of the reach of children.

OLPRUVA™ Important Safety Information (continued)

How should I or my child take OLPRUVA?

Read the detailed Instructions for Use that comes with OLPRUVA for information about the right way to prepare and take a dose of OLPRUVA.

- Take OLPRUVA exactly as prescribed by your healthcare provider.
- Your healthcare provider may change your dose if needed. Do not change your dose unless your healthcare provider tells you to.
- Your healthcare provider will prescribe OLPRUVA based on your or your child's weight.
- Take your OLPRUVA dose with food.
- If you miss a dose of OLPRUVA, take it as soon as possible that same day.
- **Do not** give or take OLPRUVA through a gastrostomy or nasogastric tube.
- If you take too much OLPRUVA, call your healthcare provider or go to the nearest hospital emergency room right away.

What are the possible side effects of OLPRUVA?

OLPRUVA can cause serious side effects, including:

- **Nervous system problems (neurotoxicity).** Call your healthcare provider right away if you or your child get any of the following symptoms during treatment with OLPRUVA:
  - sleepiness
  - nausea
  - tiredness
  - headache
  - lightheadedness
  - confusion
  - vomiting
- **Low potassium levels in your blood (hypokalemia).** Your healthcare provider will monitor your blood potassium levels during treatment with OLPRUVA and treat if needed.
- **Conditions related to swelling (edema).** OLPRUVA contains salt (sodium), which can cause swelling from salt and water retention. Your healthcare provider will decide if OLPRUVA is right for you if you have certain medical conditions that cause edema, such as heart failure, liver problems or kidney problems.

The most common side effects of OLPRUVA include:

- absent or irregular menstrual periods
- body odor
- decreased appetite
- bad taste or avoiding foods that you ate prior to getting sick (taste aversion)

Your healthcare provider may do certain blood tests to check you or your child for side effects during treatment with OLPRUVA.

These are not all of the possible side effects of OLPRUVA. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

For additional Important Safety Information see full Prescribing Information and Patient Information, including Instructions for Use, and discuss with your doctor.

Zevra Positioned for Success in Rare Disease

Significant near-term catalysts to increase shareholder value through 2H 2023

Continued Strategic Focus on Rare Disease

- Focus on delivering therapies addressing significant unmet needs in rare disease
- Leveraging unique insights and capabilities to develop rare disease therapies
- Strong relationships with rare disease community – including KOLs and advocates

Differentiated Portfolio In Rare Disease

- Arimoclomol for Niemann-Pick disease Type C (NPC); NDA filing expected in Q4 2023
- KP1077 for idiopathic hypersomnia (IH) and narcolepsy; interim data expected by end of Q3 2023, topline data H1 2024
- OLPRUVA to treat urea cycle disorders (UCDs); FDA approved product*
- EDSIVO for vascular Ehlers-Danlos syndrome (vEDS); interim Phase 3 data expected in 2024*

Creating Value

- Strong balance sheet supports investment in Zevra's portfolio and ongoing operations
- Increased and diversified revenue from multiple products
- Commercial capabilities to provide access to treatments for patients with rare diseases

** Pending Completion of Proposed Acquisition of Acer Therapeutics*

Executing on Zevra's Strategy to Become a Leading Rare Disease Therapeutics Company

ZEVRA THERAPEUTICS

Adding a complementary rare disease portfolio, accelerating revenue potential and cost synergies

Deal Consideration

- ✓ Zevra to acquire Acer Therapeutics in a stock exchange transaction for $0.61 per share, or $15M of Zevra's common stock, ~2% discount to Acer's last closing price
- ✓ Termination agreement with Relief Therapeutics on U.S. rights unlocks OLPRUVA™ value
- ✓ Contingent value rights (CVRs) of up to $76M based on achieving future commercial and regulatory milestones, as well as potential payments related to preclinical program

Portfolio Value

- ✓ OLPRUVA™ approved for adjunctive therapy to standard of care for patients with Urea Cycle Disorders
- ✓ EDSIVO™, Phase 3 program for the treatment of vascular Ehlers-Danlos syndrome (vEDS), a rare genetic disorder impacting blood vessels, expands Zevra's rare disease development pipeline
- ✓ Additional rare disease capabilities and expertise

Strategic Fit

- ✓ Highly complementary portfolio of therapies addressing rare diseases
- ✓ Significant synergies and potential cost savings across commercial organization
- ✓ Accelerates Zevra's commercial platform and capabilities to support arimoclomol launch, if approved

Details of transaction available at https://investors.zevra.com/node/12621/html

Acer Acquisition Would Accelerate Zevra's Growth into Commercial Organization and Expand Development Pipeline

ZEVRA THERAPEUTICS

PHASE 1	PHASE 2	PHASE 3	NDA	FDA APPROVED	NEXT MILESTONE
Arimoclomol **Nieman Pick Type C**					**NDA Resubmission Q4 2023**
KP1077 **Idiopathic Hypersomnia**					**Interim P2 Analysis Q3 2023**
KP1077 **Narcolepsy**					**Trial ongoing**
AZSTARYS® *serdexmethylphenidate and dexmethylphenidate* **Attention Deficit/Hyperactivity Disorder**					**On track to receive next sales milestone**
OLPRUVA™ *sodium phenylbutyrate for oral suspension* **Urea Cycle Disorder**					**Approved and commercially available in US**
EDSIVO™ *celiprolol* **Vascular Ehlers-Danlos Syndrome**					**Phase 3 trial ongoing**

Combined Portfolio

- Highly complementary portfolio targeting rare diseases
- Upcoming milestones and catalysts
- Robust pipeline with clinical and commercial assets
- Overlap of treating physicians

Urea Cycle Disorders (UCDs)

- UCDs are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes responsible for removing ammonia from the bloodstream
- Elevated ammonia levels in both symptomatic and asymptomatic patients can be neurotoxic leading to neurocognitive damage, potentially coma and even death if untreated



Current treatments:
Phenylbutyrate

1. https://www.drugs.com/slideshow/top-10-most-expensive-drugs-1274
2. HealthVerify Payer Claims data analysis 2021

Unmet Needs in Treatment of UCD

Palatability, odor, route of administration and packaging affect adherence[1]

Current Level of Unmet Need In UCD Treatments



Mean Relative Attribute Importance for UCD Treatment Adherence in a Discrete Choice Exercise



1. Acer company sponsored market research

OLPRUVA™ Has Potential to Address Unmet Needs in Treatment of UCDs

OLPRUVA: FDA approved, novel formulation of phenylbutyrate with convenient, single-dose packaging

- Potential to improve compliance through more convenient administration and palatable formulation
- Dual-coated formulation delays release in water for up to 5 minutes, rapidly dissolves in stomach
- Patent protection through 2036

Multiple opportunities for potential indication expansion for OLPRUVA

- Ongoing investigations in UCDs to determine feasibility to enhance administration flexibility options and improve bioavailability via pre-meal administration
- Other investigational life cycle indications include Maple Syrup Urine disease, a liver disorder

OLPRUVA™
(sodium phenylbutyrate)
for oral suspension

1. SIMD 2023: Edelblut J et al Quantifying Preferences for Urea Cycle Disorder Treatments Using a Discrete-Choice Experiment SIMD 2023

Niemann-Pick disease Type C (NPC)[1]

ULTRA RARE

- Estimated to occur in 1 in 100,000-120,000 live births[1]
- Approximately 1,800 patients diagnosed in the U.S. and E.U

PROGRESSIVE LYSOSOMAL STORAGE DISORDER

- Characterized by an inability of the body to transport cellular cholesterol and lipids
- Leads to organ dysfunction in brain, spleen and liver
- Ranges from fatal within the first few months after birth (neonatal period), to late onset, chronic progressive disorder that remains undiagnosed well into adulthood

SIGNIFICANT UNMET NEED

- Neuro-cognitive decline adversely impacts daily living
- Irreversible and potentially fatal disease
- Mean age of death in NPC patients is 13 years[2]
- No approved treatments exist in the U.S. for NPC

Source: (1) https://rarediseases.org/
(2) Bianconi, 2019

Arimoclomol for the Treatment of NPC

FIRST-IN-CLASS, ORAL TREATMENT

- Capsule can be swallowed whole, opened and mixed with foods/liquids or delivered through feeding tube
- Significant improvements in lysosomal and cellular function with arimoclomol treatment

EXTENSIVE CLINICAL EXPERIENCE WITH DEMONSTRATED SAFETY

- Studied in ten Phase 1, four Phase 2, and three Phase 2/3 trials
- No significant safety findings identified to date (500+ patients treated)
- Positive efficacy demonstrated in NPC trial (NPC-002)
- Data from the four-year open-label extension of Phase 2/3 trial showed trends consistent with the positive results from the 1-year double-blind phase

ADVANTAGEOUS REGULATORY DESIGNATION

- Orphan Drug Designation for NPC in U.S. and EU
- Fast-Track Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation from the FDA for NPC
- If approved by FDA, Zevra will receive Rare Pediatric Disease Priority Review Voucher

Pre-Submission Meeting with FDA was Productive and Collaborative

Complete Response Letter (CRL) and FDA feedback gathered through multiple interactions/meetings has provided added clarity on resubmission package.

COMPLETE RESPONSE LETTER	ZEVRA'S ONGOING RESPONSE
1 Sufficiency of validation and reliability of the Niemann-Pick type C Clinical Severity Scale (NPCCSS) instrument	Additional evidence being provided to support use of the NPCCSS as the primary instrument in measuring NPC disease progression
2 Appropriateness of how to handle data affected by certain patient events and method of primary endpoint analysis	Using FDA preferred primary analysis and supportive additional analyses
3 Robustness of confirmatory evidence to support single efficacy trial	Additional data from multiple new nonclinical studies being provided, as well as data from the 4-year open label extension of the Ph2/3 clinical trial

Expected Commercial Effectiveness and Synergies between OLPRUVA™ and Arimoclomol

Complementary portfolios have the potential to provide scale and efficiency

Prescribing Physicians/ Specialty Pharmacies

Patient Services Across Indications

Data Management Systems

Combined cross-functional team with rare disease experience

Commercial Contracts and Sales Organization

Overlap in Prescribers and Centers of Excellence between UCD and NPC indications allow for efficient team approach

Arimoclomol Additional Ways to Create Value for Patients and Shareholders

EAP Provides Patient Data, Revenue Stream And Foundation For Commercial Launch

- Data from patients in EAP support re-submission of NDA
- Revenue from French EAP reimbursements
  - The only system that reimburses for treatment prior to regulatory approval
  - Ongoing net reimbursements of ~$2M per quarter
- **Potential first adopters of arimoclomol post-approval**
  - Early access and other compassionate use programs active in the U.S., Germany, France, Italy, Denmark, Switzerland and the U.K.

Rare Pediatric Disease Priority Review Voucher

- Upon approval, Zevra will receive a Rare Pediatric Disease Priority Review Voucher
  - Estimated value of ~$100M
  - Program could eventually end, making these vouchers more scarce

Need for Better Treatments for Idiopathic Hypersomnia

RARE

- 10.3 IH patients per 100,000 people in the US[1]
- ~37,000 diagnosed & actively seeking treatment[2]
- Total population may be much larger

SYMPTOMS HIGHLY DEBILITATING

- Chronic daytime sleepiness
- Long and unrefreshing naps
- Extreme difficulty waking
- Excessively long sleep times (~25% of patients “long sleepers”, >10hrs)
- Brain fog, memory problems, errors in habitual activities, mind blank and attention problems

CURRENT TREATMENTS DON’T ADDRESS NEED

- Patients rated current medication effectiveness as poor (5.4 on a 10-point scale)[3]
- Tolerable stimulant treatment doses are inadequate to treat brain fog
- Comorbidities complicate treatment (cardiovascular and patient demographics)
- Potential DDI with contraceptives, antidepressants, antihistamines

Sources: (1) https://doi.org/10.1093/sleep/zsy061.624
(2) https://www.sleepcountshcp.com/what-is-idiopathic-hypersomnia
(3) https://www.sleepcountshcp.com/idiopathic-hypersomnia-treatment-options

KP1077 – Novel Approach to Rare Sleep

ZEVRA THERAPEUTICS

SERDEXMETHYLPHENIDATE FOR RARE SLEEP DISORDERS

- Two dosing regimens being explored
  - Once daily at night
  - 2x daily-once in the morning and once at night
- Potential to address primary IH symptoms: sleep inertia and brain fog

IMPROVED SAFETY & TOLERABILITY OVER EXISTING TREATMENTS

- Greater tolerability and lower cardiovascular effects could allow for higher, more effective dosing (i.e. greater efficacy)
- No DDI potential with hormonal contraceptives; antidepressants

REGULATORY & IP ADVANTAGES

- Orphan Drug designation in IH
- Potentially eligible for other expedited approval pathways
- Solid IP through 2037 and potentially beyond
- SDX designated C-IV by DEA

Phase 1 clinical trial results confirmed cardiovascular safety risk of SDX improved vs. immediate-release and long-acting formulations of Ritalin® and SDX provided higher total exposure to d-MPH

Two Dosing Regimens Being Explored to Achieve Sustained Symptom Management



Plasma concentrations were estimated based on data collected in study KP879.101

Predicted PK is shown for steady state of 240 mg SDX based on single oral dose of 240 mg SDX CI in KP879.101

KP1077 Opportunity in Rare Sleep Disorders

Lead clinical program in idiopathic hypersomnia (IH) with potential to expand into narcolepsy



Idiopathic Hypersomnia

- Ongoing Phase 2 clinical trial was initiated in December 2022
- Designated by the FDA as an orphan drug, and potentially eligible for fast-track review status, as well as designation as a breakthrough treatment
- Interim data from Phase 2 clinical trial expected end of Q3 2023
- Top-line data expected H1 2024

Narcolepsy

- Expanded clinical program for KP1077 by opening IND in April 2023
- Phase 1 trial enrollment underway
- Evaluate the potential to initiate narcolepsy Phase 3 trial based on IH Phase 2 results
  - Seek to leverage key data points from IH program to expedite narcolepsy program

Update on Partnered Asset: AZSTARYS®

Commercial Product Delivering Growing Value

Surpassed $25 million in annual net sales; Zevra earned $5 million net sales milestone

- Q2 2023 royalties were $0.8M
- Based on net sales trend, Zevra expected to earn second net sales milestone payment of $10M by the end of 2023

INDICATED FOR TREATMENT OF ADHD
IN PATIENTS 6 YEARS OF AGE AND OLDER

APPROVED BY U.S. FDA
IN MARCH 2021

COMMERCIALIZED IN U.S. BY **CORIUM INC**

Significant Value Creation through Continued Execution

Arimoclomol for Niemann-Pick Type C

- Pre-submission meeting with FDA was productive and collaborative; no change in strategy
- Full NDA package expected to be submitted in Q4 2023
- Building key functions and capabilities to support successful arimoclomol launch, if approved
- EAPs and patient advocacy relationships to support product adoption at launch

KP1077 for Rare Sleep Disorders

- Phase 2 IH trial is actively enrolling in the U.S.
- Interim Phase 2 data are expected by end of Q3 2023
- Topline Phase 2 data in IH are expected to be reported in the H1 2024 based on the pace of enrollment
- Phase 1 clinical trial in narcolepsy program ongoing

Acer Acquisition

- Potential to increase and diversify revenue with addition of commercial asset, OLPRUVA
- Expanded development pipeline with the addition of EDSIVO, intended for the treatment of vEDS
- Capital efficient transaction with potential to capture cost synergies via complementary portfolio

Corporate and Financial

- Net revenue of $8.5M for Q2 2023
- AZSTARYS® $25M net sales milestone reached; Zevra earned $5M milestone payment
- Expect to earn next AZSTARYS net sales milestone of $10M this year
- Cash, cash equivalents and investments of $87.4M as of June 30, 2023
- Leveraging balance sheet to create long-term value

Thank You

ZEVRA THERAPEUTICS